U.S. market Open. Closes in 3 hours 39 minutes

APLS | Apellis Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for APLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -9.93 -23.05
PEG Ratio (TTM) -0.48 15.47
P/S Ratio (TTM) 5.26 49.46
P/B Ratio (TTM) 12.51 18.87
P/FCF Ratio (TTM) -7.95 -3.27
Price to 5YR AVG Earnings Ratio -4.60 -3.55
Price to 5YR AVG FCF Ratio -7.91 -9.37

Profitability (25%)

Company Industry
ROA (TTM) -36.81% -5.14%
ROE (TTM) -139.03% 16.69%
Net Profit Margin (TTM) -53.90% -1,583.93%
ROIC 5YR AVG 310.84% 15.15%

Growth (42%)

4QTR AVG 3YR AVG 5YR AVG
EPS 23.34% -65.86% -27.90%
Revenue 21.41% -24.48% 73.14%
Net Income 22.56% -90.24% -47.83%
Cash Flow 21.84% -95.92% -58.95%

Health (32%)

Company Industry
Current Ratio (TTM) 5.08 6.13
Quick Ratio (TTM) 4.18 5.85
D/E Ratio (TTM) 1.75 -15.81
Interest Coverage (TTM) -19.76 -1.57
Piotroski F-Score 2 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.23 0.17
Shares Outstanding Growth 5YR AVG 17.01% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙